Cipla: Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound) 100 mg/vial Single-Dose Vial (Protein-bound Paclitaxel) on 10th April 2025